Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
NCT00137332
Last updated date
ABOUT THIS STUDY
The purpose of this study is to learn the effects of a test drug on heart rhythms, which may
become life-threatening if left untreated, and to provide data to see if the drug is well
tolerated and safe.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Arrhythmia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Patients with or without ICDs (implantable cardioverter defibrillators)
- Patients undergoing an electrophysiology study for evaluation of ventricular rhythm
- Patients with a history of heart disease
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Patients with uncontrolled blood pressure
- Patients with certain cardiac risk factors
- Patients with significant kidney or liver problems
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
ArrhythmiaStudy Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
NCT00137332
- Sacramento, California
- San Francisco, California
- Washington, District of Columbia
- Orlando, Florida
- Peoria, Illinois
- Iowa City, Iowa
- Worcester, Massachusetts
- Ann Arbor, Michigan
- Lansing, Michigan
- Southfield, Michigan
- Minneapolis, Minnesota
- Newark, New Jersey
- Winston-Salem, North Carolina
- Cleveland, Ohio
- Cleveland, Ohio
- Hershey, Pennsylvania
- Wynnewood, Pennsylvania
- Falls Church, Virginia
- Norfolk, Virginia
- Edmonton, Alberta
- Vancouver, British Columbia
- Victoria, British Columbia
- St-Johnâ s, Newfoundland and Labrador
- Halifax, Nova Scotia
- London, Ontario
- Newmarket, Ontario
- Toronto, Ontario
- Fleurimont, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Sainte-Foy, Quebec
- Sherbrooke, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ArrhythmiaSingle Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously
NCT00510029
- Philadelphia, Pennsylvania
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ArrhythmiaStudy Evaluating GAP-486 in Heart Rhythm
NCT00137293
- San Francisco, California
- Washington, District of Columbia
- Hershey, Pennsylvania
- Ottawa, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
ArrhythmiaAtorvastatin For The Reduction Of Ventricular Arrhythmias
NCT00457340
- Aalst,
- Antwerpen,
- Brugge,
- Edegem,
- Gent,
- Hasselt,
- Leuven,
- Athens,
- Crete,
- Rio Patra,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease | |||
| Official Title ICMJE | A Study of the Effects GAP-486 on Ventricular Tachyarrhythmia Induction | |||
| Brief Summary | The purpose of this study is to learn the effects of a test drug on heart rhythms, which may become life-threatening if left untreated, and to provide data to see if the drug is well tolerated and safe. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 2 | |||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment | |||
| Condition ICMJE | Arrhythmia | |||
| Intervention ICMJE |
| |||
| Study Arms ICMJE | Not Provided | |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Terminated | |||
| Enrollment ICMJE | 90 | |||
| Original Enrollment ICMJE | Same as current | |||
| Actual Study Completion Date ICMJE | October 2006 | |||
| Primary Completion Date | Not Provided | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Canada, United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00137332 | |||
| Other Study ID Numbers ICMJE | 3163K1-202 | |||
| Has Data Monitoring Committee | Not Provided | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Not Provided | |||
| Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Verification Date | December 2007 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||